Congressional Budget Office director Peter Orszag is becoming the apostle of comparative effectiveness research. Orszag believes a national effort will reduce health care costs over the long term-and he's telling anyone who will listen.
Congressional Budget Office director Peter Orszag is on a mission: sell the idea of a national effort on comparative effectiveness research as a way to control rising health care costs.
Orszag has taken to Capitol Hill and the conference circuit to argue that with the right incentives, a national effort...
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.
